<DOC>
	<DOCNO>NCT02220842</DOCNO>
	<brief_summary>This open-label , multicenter , global study design assess safety , tolerability , preliminary efficacy , pharmacokinetics intravenous atezolizumab ( MPDL3280A ) obinutuzumab participant refractory relapse follicular lymphoma ( FL ) atezolizumab obinutuzumab tazemetostat administer participant refractory relapse diffuse large B-cell lymphoma ( DLBCL ) . The anticipated duration study approximately 4.5 year .</brief_summary>
	<brief_title>A Safety Pharmacology Study Atezolizumab ( MPDL3280A ) Administered With Obinutuzumab Tazemetostat Participants With Relapsed/Refractory Follicular Lymphoma Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically document , CD20positive , relapse refractory ( define relapse within 6 month previous treatment ) FL DLBCL ( include primary mediastinal large Bcell lymphoma [ PMLBCL ] ) Bone marrow biopsy screening ( unless perform within 3 month prior screen ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Life expectancy great equal ( &gt; = ) 12 week Has QT interval correct Fridericia 's formula ( QTcF ) less equal ( &lt; = ) 480 millisecond ( msec ) At least one bidimensionally measurable nodal lesion &gt; 1.5 cm long diameter compute tomography ( CT ) scan MRI , define Lugano Classification Adequate hematologic endorgan function Archival tumor tissue For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive method result failure rate &lt; 1 % per year treatment period least 90 day last dose atezolizumab 18 month last dose obinutuzumab , whichever long For men : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure agreement refrain donate sperm Known central nervous system lymphoma , leptomeningeal lymphoma , histologic evidence transformation indolent lymphoma highgrade DLBCL Grade 3b FL , small lymphocytic lymphoma ( SLL ) , Waldenstr√∂m 's macroglobulinemia ( WM ) lymphoma subtypes except state inclusion criterion Uncontrolled pleural effusion , pericardial effusion , ascites require recurrent drainage procedure ( monthly frequently ) ; participant indwell catheter eligible Uncontrolled hypercalcemia symptomatic hypercalcemia require continue use bisphosphonate therapy denosumab History severe allergic anaphylactic reaction monoclonal antibody therapy Has prior exposure tazemetostat inhibitor ( ) enhancer zeste homolog 2 ( EZH2 ) Regular treatment corticosteroid within 2 4 week prior start Cycle 1 , unless administer indication nonHodgkin 's lymphoma dose equivalent &lt; 30 mg/day prednisone/prednisolone Pregnant lactate woman History autoimmune disease Participants history confirm progressive multifocal leukoencephalopathy ( PML ) Participants prior allogeneic bone marrow transplantation prior solid organ transplantation History idiopathic pulmonary fibrosis , organize pneumonia ( e.g. , bronchiolitis obliterans ) , druginduced pneumonitis , idiopathic pneumonitis , evidence active pneumonitis per chest CT scan screening . History radiation pneumonitis radiation field ( fibrosis ) allow Positive test Human Immunodeficiency Virus ( HIV ) History chronic hepatitis B infection positive test result active chronic hepatitis B hepatitis C Significant cardiovascular disease , cardiac disease ( New York Heart Association Class II great ) , myocardial infarction within previous 3 month , unstable arrhythmia , unstable angina Hypersensitivity prior treatment obinutuzumab Fludarabine Campath within 12 month prior study entry Prior treatment CD137 agonists immune checkpoint blockade therapy , include antiCTLA4 , antiPD1 , antiPDL1 therapeutic antibody Treatment systemic immunostimulatory agent ( include limit interferon , interleukin2 ) within 6 week 5 halflives drug , whichever short , prior Cycle 1 , Day 1 Treatment systemic immunosuppressive medication , include limited prednisone , cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor ( antiTNF ) agent within 2 week prior Cycle 1 , Day 1 ; inhale corticosteroid mineralocorticoid allow Participants active tuberculosis ( TB ) exclude clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>